Cure My Disease

Don't miss your cure!

 Log in / Sign up

A nerve block may ease pain after gastric bypass and reduce opioid use

NCT ID NCT03367728

Symptom relief Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This trial tests whether injecting a local anesthetic called ropivacaine into the abdominal wall during gastric bypass surgery can reduce the need for opioid painkillers in the first 24 hours after the operation. Half of the 148 participants receive the nerve block, while the other half receive a placebo (saltwater) injection. Researchers also measure breathing recovery and pain scores to see if the block improves overall recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ropivacaine, a local anesthetic injected as a nerve block during surgery
What this could lead to
If it works, this could point toward a standard way to manage pain after gastric bypass with fewer opioids, leading to faster recovery and less risk of opioid dependence.
What could go wrong
The trial is relatively small and the benefit may be modest. The nerve block might not reduce opioid use enough to matter, and there is a small risk of complications from the injection itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

148 people

The number who actually took part.

Started

Nov 2018

Finished

Mar 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing Roux-en-Y gastric bypass surgery; * Patients who able to tolerate general anesthetic and pneumoperitoneum; * Patients who able to provide informed consent for the surgery; * Patients over the age of 18 years; Exclusion Criteria: * Patient undergoing planned sleeve gastrectomy (intra-op conversion to sleeve gastrectomy after delivery of Ropivacaine/placebo will be included and analyzed using intention-to-treat approach) * Patients with an allergy to local anesthetics * Patients with severe underlying cardiovascular disease (ie: congestive heart failure, conduction abnormalities, and ischemic heart disease) * Patients with chronic renal disease Stage 3 or greater (Creatinine clearance less than 60mL/min) * Patients with hepatic dysfunction Child-Pugh Class B or C * Patients with previous foregut surgery including esophageal, gastric, liver, and pancreas resections * Patients weighing less than or equal to 100 kilograms as measured in the pre-admission unit * Patients enrolled in any other study involving involve tissue biopsy. * Patients with Chronic Pain and Chronic Opioid use- Oral Morphine Equivalent of \>100mg/day

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery candidate are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric surgery candidate

Contacts and locations

Locations

  • The Ottawa Hospital

    Ottawa, Ontario, K1Y 4E9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.